Eric A. Vasiliauskas, MD
4.9
23 Reviews
310-423-4100
Fax: 310-423-0146
4.9
23 Reviews
Eric A. Vasiliauskas, MD
Scheduling
In person visits
Fax: 310-423-0146
Inflammatory Bowel Disease Center
8720 Beverly Blvd, Lower Level
Los Angeles, CA
34.07568 -118.38077From You
4.9
23 Reviews
Eric A. Vasiliauskas, MD
Languages
- English,
- Lithuanian,
- Spanish,
Gender
Male
Experience
38 Years
Locations
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- IM Gastroenterology
Sub Specialties
A focused area of clinical knowledge and skills within a specialty. Example: a neurology specialist focused on stroke treatment.
1
- Inflammatory Bowel Disease
Programs
Cedars-Sinai clinical programs this provider is part of:
4
Research Areas
Titles
- Associate Clinical Director, Inflammatory Bowel Disease Program
Education & Training
-
Cedars Sinai Medical Center
Fellowship - Completed 1993
-
Children's Hospital Los Angeles
Fellowship - Completed 1992
-
Children's Hospital Los Angeles
Residency - Completed 1989
-
Children's Hospital Los Angeles
Internship - Completed 1988
-
University of Illinois College of Medicine
Medical School - Completed 1984
Achievements
-
2
Board Certifications
-
7
Awards and Honors
-
6
Publications
Board Certifications
-
Pediatrics
American Board of Pediatrics
-
Peds - Gastroenterology
American Board of Pediatrics
Awards and Honors
- Best Doctors in Southern California, Recognized by Peers
- Member, Cedars-Sinai Institutional Review Board
- National Crohn's & Colitis Foundation's Patient Education Committee
- National Crohn’s & Colitis Foundation’s Professional Education Committee
- Member, Rapid Activation IRB
- North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Committee
- Vice-Chair, IRB-3
Publications
- Mow WS, Lo SK, Targan SR, Dubinsky MC, Treyzon L, Abreu-Martin MT, Papadakis KA, Vasiliauskas EA. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004;2(1):31-40.
- Dubinsky MC, Yang HY, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122(4):904-915.
- Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, van Hogezand RA, Braakman T, DeWoody KL, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761-769.
- Shih DQ, Nguyen M, Zheng L, Ibanez P, Mei L, Kwan LY, Bradford K, Ting C, Targan SR, Vasiliauskas EA. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther. 2012;36(5):449-458.
- Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang HY, Targan SR. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47(4):487-496.
- North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Oliva-Hemker M, Ziring D, Saeed S, Bousvaros A. Your Child with Inflammatory Bowel Disease: A Family Guide for Caregiving. 2017.